Tata India Pharma & Healthcare Fund-Regular Plan-Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 28-12-2015
AUM:
₹ 1,310.51 Cr
Expense Ratio
2.1%
Benchmark
NIFTY Pharma TRI
ISIN
INF277K016A9
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Meeta Shetty, Rajat Srivastava
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | -0.83 | 21.55 | 14.19 |
| Nifty Pharma TRI | 2.08 | 21.98 | 12.03 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
29.9519
Last change
-0.1 (-0.3412%)
Fund Size (AUM)
₹ 1,310.51 Cr
Performance
11.49% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund Manager
Meeta Shetty, Rajat Srivastava
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 7.88 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 5.87 |
| ABBOTT INDIA LIMITED EQ | 5.48 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 5.01 |
| HEALTHCARE GLOBAL ENTERPRISES LTD EQ | 4.84 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 4.76 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 4.14 |
| RAINBOW CHILDRENS MEDICARE LIMITED EQ | 3.77 |
| IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 3.72 |
| JB Chemicals & Pharmaceuticals Limited | 3.52 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 94.99 |
| Chemicals | 3.69 |